Literature DB >> 8795498

Endocrine treatment of cancer.

T Gulliford1, R J Epstein.   

Abstract

Cancer has been treated by hormonal manipulation for over 100 years. Although therapeutic progress during this period has resulted mainly from clinical observation, more rational treatment approaches are now emerging from insights into the molecular basis of hormone-responsiveness. Among these are the recognition that hormonal signalling effects are transduced via specific receptor proteins, and the possibility that tumour lysis by hormonal therapies is effected by triggering of a programmed cell death pathway. Clinical progress has already been achieved through basic advances: receptor assays, for example, now permit prediction of treatment benefit in various settings. However, much remains to be learned about the mechanism and application of hormonal anticancer treatments.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8795498      PMCID: PMC1295886          DOI: 10.1177/014107689608900808

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  24 in total

Review 1.  The clinical biology of hormone-responsive breast cancer.

Authors:  R J Epstein
Journal:  Cancer Treat Rev       Date:  1988-03       Impact factor: 12.111

2.  Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.

Authors:  P Komminoth; E K Kunz; X Matias-Guiu; O Hiort; G Christiansen; A Colomer; J Roth; P U Heitz
Journal:  Cancer       Date:  1995-08-01       Impact factor: 6.860

3.  Female sex steroid receptors in postmenopausal endometrial carcinoma and biochemical response to an antiestrogen.

Authors:  R Mortel; C Levy; J P Wolff; J C Nicolas; P Robel; E E Baulieu
Journal:  Cancer Res       Date:  1981-03       Impact factor: 12.701

4.  Androgen receptor gene mutations in human prostate cancer.

Authors:  J R Newmark; D O Hardy; D C Tonb; B S Carter; J I Epstein; W B Isaacs; T R Brown; E R Barrack
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

5.  HER-2/neu oncogene protein and prognosis in breast cancer.

Authors:  A K Tandon; G M Clark; G C Chamness; A Ullrich; W L McGuire
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

Review 6.  The use of the long-acting somatostatin analogue, octreotide acetate, in patients with islet cell tumors.

Authors:  P N Maton
Journal:  Gastroenterol Clin North Am       Date:  1989-12       Impact factor: 3.806

7.  Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation.

Authors:  N Kyprianou; H F English; J T Isaacs
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

8.  Tamoxifen and endometrial carcinoma: alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia.

Authors:  J A Carlson; J C Allegra; T G Day; J L Wittliff
Journal:  Am J Obstet Gynecol       Date:  1984-05-15       Impact factor: 8.661

9.  Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer.

Authors:  J R Sainsbury; J R Farndon; G V Sherbet; A L Harris
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

10.  HER-2/neu amplification predicts poor survival in node-positive breast cancer.

Authors:  A Borg; A K Tandon; H Sigurdsson; G M Clark; M Fernö; S A Fuqua; D Killander; W L McGuire
Journal:  Cancer Res       Date:  1990-07-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.